Detalhe da pesquisa
1.
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.
Scand J Gastroenterol
; 58(1): 25-33, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996928
2.
Longitudinal evolution of catheter-related bloodstream infections, kidney function and liver status in a nationwide adult intestinal failure cohort.
Scand J Gastroenterol
; 57(7): 763-767, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35174757
3.
Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study.
Scand J Gastroenterol
; 57(8): 936-941, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35238727
4.
Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
Scand J Gastroenterol
; 56(8): 906-913, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34154506
5.
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland.
Scand J Gastroenterol
; 56(6): 661-670, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33820465
6.
Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases.
Scand J Gastroenterol
; 55(1): 34-40, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841064
7.
Fragmented management of long-term parenteral support for adult intestinal failure in Finland.
Scand J Gastroenterol
; 54(4): 414-418, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30915863
8.
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Scand J Gastroenterol
; 54(6): 718-725, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31184512
9.
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.
Biologicals
; 58: 50-56, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755369
10.
The impact of an adaptation course on health-related quality of life and functional capacity of patients with inflammatory bowel disease.
Scand J Gastroenterol
; 53(9): 1074-1078, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30175636
11.
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
Scand J Gastroenterol
; 53(2): 158-167, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29258369
12.
Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Scand J Gastroenterol
; 52(12): 1348-1353, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838273
13.
Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
Scand J Gastroenterol
; 52(3): 284-290, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27806638
14.
Detailed Follow-up Study of Pediatric Orofacial Granulomatosis Patients.
J Pediatr Gastroenterol Nutr
; 65(4): 388-393, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28425922
15.
Does oral α-galactosidase relieve irritable bowel symptoms?
Scand J Gastroenterol
; 51(1): 16-21, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26133538
16.
Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy: A Multicenter Retrospective Study.
Dig Dis Sci
; 61(7): 2033-40, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27007135
17.
[Exemplary cases of individualization of biological therapy]. / Esimerkkitapauksia biologisen hoidon yksilöllistämisestä.
Duodecim
; 132(4): 387-90, 2016.
Artigo
em Fi
| MEDLINE | ID: mdl-27017791
18.
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
Scand J Gastroenterol
; 50(1): 74-80, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25523558
19.
Surgical rehabilitation of short and dysmotile intestine in children and adults.
Scand J Gastroenterol
; 50(2): 153-61, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25421304
20.
The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
Scand J Gastroenterol
; 49(4): 434-41, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24597837